Zelquistinel
Small moleculeexperimental
Clinical trial activity
4 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Dec 9, 2016 (NCT04981561)
Timeline
Indications
Mechanism of action
- Glutamate [NMDA] receptor subunit 3AMODULATOR
GRIN3A modulator
Chemistry & pharmacology
Loading structure…
SMILES
C[C@@H](O)[C@@H](C(N)=O)N1C[C@@]2(CCCN2C(=O)OC(C)(C)C)C1=O- Mol. weight
- 327.38 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL5314944 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07115329 | Phase 2 | Nov 30, 2025 | Gate Neurosciences, Inc, Worldwide Clinical Trials |
| NCT07099989 | Phase 1 | Jul 24, 2025 | Dr. Vince Clinical Research, Gate Neurosciences, Inc |
| NCT06547489 | Phase 2 | Sep 30, 2024 | Gate Neurosciences, Inc |
| NCT04981561 | Phase 1 | Dec 9, 2016 | Gate Neurosciences, Inc |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Gate Neurosciences, Inc | For profit | 4 | 4 | 2 | 2016 |
| Dr. Vince Clinical Research | For profit | 1 | 0 | 1 | 2025 |
| Worldwide Clinical Trials | For profit | 1 | 0 | 1 | 2025 |
3 organizations
Page 1 / 1